WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company
focused on bioprocessing technology leadership, today announced that management will participate in the 14th Annual
Craig-Hallum Institutional Investor Conference, to be held in Minneapolis on Wednesday, May 31, 2017.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and
commercialization of highly innovative products used to improve the biological drug manufacturing process. Our portfolio includes
Protein products (Protein A affinity ligands, cell culture growth factors), Chromatography products (OPUS® pre-packed columns,
chromatography resins, ELISA kits) and Filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF cassettes). Our bioprocessing
products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing
organizations worldwide. We are the leading manufacturer of Protein A ligands, a critical component of Protein A resins that are
the industry standard for downstream separation and purification of monoclonal antibody-based therapeutics. Our growth factors are
a key component of cell culture media used in upstream processes to accelerate cell growth and productivity in a bioreactor. Our
innovative line of OPUS® chromatography columns, used in downstream processes for bench-scale through clinical-scale purification
needs, are delivered pre-packed with our customers’ choice of resin and bed height. Our XCell™ ATF Systems, available in stainless
steel and single-use configurations, continuously eliminate waste from a bioreactor to concentrate cells in upstream processes.
TangenX Sius™ TFF single-use cassettes and hardware are used for biologic drug concentration in downstream formulation processes.
Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Shrewsbury,
MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which are not strictly historical statements including, without
limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to
time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any
forward-looking statements, except as required by law.
Contact: Sondra Newman snewman@repligen.com
